H. Lundbeck lines up acquisition financing for Alder

---

Danish pharmaceuticals company H. Lundbeck has agreed to acquire NASDAQ-listed peer Alder BioPharmaceuticals (Alder) for USD1.95bn.

H. Lundbeck is set to fund the acquisition through its existing cash resources and bank financing.

Alder stockholders have been offered an upfront